<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597294</url>
  </required_header>
  <id_info>
    <org_study_id>Gastric CHIMERA Trial</org_study_id>
    <secondary_id>2020-001419-25</secondary_id>
    <secondary_id>2019/ABM/01/00020-00</secondary_id>
    <nct_id>NCT04597294</nct_id>
  </id_info>
  <brief_title>Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence</brief_title>
  <acronym>CHIMERA</acronym>
  <official_title>A Randomized, Multicenter Clinical Trial Comparing the Combination of Perioperative FLOT4 Chemotherapy and Preoperative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Plus Gastrectomy to Perioperative FLOT4 Chemotherapy and Gastrectomy Alone in Patients With Advanced Gastric Cancer at High Risk of Peritoneal Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to evaluate the efficacy of perioperative FLOT4 chemotherapy in&#xD;
      combination with perioperative hyperthermic intraperitoneal chemotherapy (HIPEC) in patients&#xD;
      with advanced gastric cancer at high risk of peritoneal metastases. The impact of treatment&#xD;
      on peritoneal recurrence and survival over 6 months, 1, 3 and 5 years will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multicenter, clinical trial in which 598 patients with advanced gastric&#xD;
      cancer at high risk of peritoneal metastases are randomly allocated to receive either&#xD;
      preoperative hyperthermic intraperitoneal chemotherapy (HIPEC) plus gastrectomy (experimental&#xD;
      group) or gastrectomy alone (control group). All patients, regardless of allocation, will&#xD;
      additionally receive 4 cycles of FLOT4 chemotherapy (docetaxel 60 mg/m2, oxaliplatin 85&#xD;
      mg/m2, leucovorin 200 mg/m2 and 5-fluorouracil 2600 mg/m2) before surgery Â± HIPEC and 4&#xD;
      cycles of FLOT4 chemotherapy after gastrectomy. The main outcome is frequency of peritoneal&#xD;
      recurrence by 6-months post-operative. Patients will be followed for 5 years and undergo&#xD;
      additional evaluations at 6 months, 1 year, 3 and 5 years.&#xD;
&#xD;
      The study will take place at 7 hospitals across Poland. All participating centers have the&#xD;
      equipment and skills to perform all necessary procedures in this study. The below centers&#xD;
      specialize in the treatment of stomach cancer with many documented years of experience. They&#xD;
      are trained in the maintenance of a register, possess the skills to conduct appropriate&#xD;
      research analyses and are equipped with a system for assessing the quality of both surgical&#xD;
      and oncological treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization 1:1</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritoneal recurrence rate</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of peritoneal recurrences at 6 month time from randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
    <description>Overall survival at 6 month follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival at 3 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival at 5 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>3 years</time_frame>
    <description>Locoregional recurrence rate at 3 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic recurrence rate</measure>
    <time_frame>3 years</time_frame>
    <description>Systemic recurrence rate at 3 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>Locoregional recurrence rate at 5 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>Systemic recurrence rate at 5 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>6 months</time_frame>
    <description>According to CTCAE version 5 and Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related quality of life assessed by Quality Of Life Questionnaire (QLQ) C30 version 3.0</measure>
    <time_frame>6 months</time_frame>
    <description>Score range 0-100, higher score represents a higher (better) level of functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related quality of life assessed by Quality of Life Questionnaire-Stomach (STO22)</measure>
    <time_frame>6 months</time_frame>
    <description>Score range 0-100, higher scores represent worse quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Perioperative FLOT + prophylactic HIPEC + surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 4 doses of preoperative FLOT chemotherapy diagnostic laparoscopy will be performed - patients without distant metastases will be randomised, in those randomised to experimental arm HIPEC with irinotecan will be performed (a dose of 300 mg/m2 body surface area will be administered over 45 minutes at a temperature of 42 degrees Celsius)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perioperative FLOT + surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment regimen for advanced gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>FLOT4 + HIPEC + Surgery</intervention_name>
    <description>HIPEC with irinotecan after 4 doses of preoperative FLOT4 chemotherapy</description>
    <arm_group_label>Perioperative FLOT + prophylactic HIPEC + surgery</arm_group_label>
    <other_name>Prophylactic HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>FLOT4 + Surgery</intervention_name>
    <description>Perioperative FLOT4 chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery</description>
    <arm_group_label>Perioperative FLOT + surgery</arm_group_label>
    <other_name>Perioperative FLOT4 + Surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gastric cancer confirmed histopathologically in tumor specimens.&#xD;
&#xD;
          -  Age 18-75 years.&#xD;
&#xD;
          -  Advanced gastric cancer cT3 / cT4a / N0-3b.&#xD;
&#xD;
          -  No distant metastases on computed tomography (CT) scan of the chest, abdomen and&#xD;
             pelvis (cM0).&#xD;
&#xD;
          -  Written consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No clear histopathological confirmation of gastric cancer.&#xD;
&#xD;
          -  Age &gt; 75 years.&#xD;
&#xD;
          -  Poor general condition (Performance Status 3 or more on the Eastern Cooperative&#xD;
             Oncology Group (ECOG)/World Health Organization scale).&#xD;
&#xD;
          -  Previous abdominal surgery (including oncological surgery), other than laparoscopic&#xD;
             cholecystectomy or appendectomy (open or laparoscopic).&#xD;
&#xD;
          -  Pregnancy and lactation.&#xD;
&#xD;
          -  Refusal to participate or an inability to provide written consent.&#xD;
&#xD;
          -  Coexisting cancer in another location.&#xD;
&#xD;
          -  Systemic treatment or radiotherapy for another cancer.&#xD;
&#xD;
          -  Dysphagia requiring surgical treatment (gastric resection or nutritional jejunostomy)&#xD;
             before starting neoadjuvant treatment and indication for accelerated surgery for other&#xD;
             reasons.&#xD;
&#xD;
          -  Disqualification for perioperative FLOT4 chemotherapy as decided by a multi-specialist&#xD;
             consultation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Richter, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Jagiellonian University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Richter, Professor</last_name>
    <phone>+48124002400</phone>
    <email>piotr.richter@uj.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of General, Oncological, Gastroenterological Surgery and Transplantology</name>
      <address>
        <city>Krakow</city>
        <state>Lesser Poland Voivodship</state>
        <zip>30-688</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Richter, Professor</last_name>
      <phone>+48124002400</phone>
      <email>piotr.richter@uj.edu.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Radoslaw Pach, MD, Ph D</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIPEC</keyword>
  <keyword>FLOT4</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Lymphadenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

